CopyMark Law Group
4.9/5
Drawing for JP JAZZ PHARMACEUTICALS

USPTO serial 98726519

JP JAZZ PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 7680334Status 700Registered
Filing date
Status date
Registration date
Feb 4, 2025
Examiner
STIGLITZ, SUSAN R
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with JP JAZZ PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Olsen

Michael T. Olsen Winthrop & Weinstine, P.A.225 South 6th Street, Suite 3500Minneapolis, MN 55402United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for the treatment and prevention of cancer, psychiatric diseases and disorders, central nervous system conditions, pain, sleep disorders, narcolepsy, schizophrenia, and for use in oncology and hematology; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations acting on the central nervous system; pain relief medication; pharmaceutical preparations for use in the treatment and/or management of sleep disorders; pharmaceutical preparations for the treatment of narcolepsy; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for use in oncology and hematologyACTIVEJun 7, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 21, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 4, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Feb 4, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 17, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 17, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 11, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 22, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 22, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Nov 22, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 22, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 22, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 19, 2024DOCKASSIGNED TO EXAMINER—
Nov 10, 2024MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Nov 10, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 30, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance